Chiara Alfare | Cardiovascular Disease After Preeclampsia | Research Excellence Award

Published on by Cell Biologist

Mrs. Chiara Alfare | Cardiovascular Disease After Preeclampsia | Research Excellence Award

University of Parma | Italy

Chiara Alfarè is a resident in Gynecology and Obstetrics at the University of Parma with a strong academic interest in maternal–fetal medicine and cardiovascular complications of pregnancy. She holds a medical degree in Medicine and Surgery and gained valuable international research experience through a six-month placement at University Medical Center Hamburg-Eppendorf (UKE), where she worked with leading experts in reproductive immunology and obstetric medicine. Her research has contributed to the peer-reviewed review article “Predicting Cardiovascular Disease After Preeclampsia: Emerging Tools and Early Detection Approaches” published in the Journal of Reproductive Immunology. Her work explores long-term cardiovascular risk following preeclampsia and emphasizes early prediction and prevention strategies. In addition, she is currently involved in an innovative project applying artificial intelligence to optimize decision-making regarding the mode of delivery. She has received recognition for her scientific contributions, including a Best Poster Presentation award at a major European scientific meeting.

Featured Publications


Predicting Cardiovascular Disease After Preeclampsia: Emerging Tools and Early Detection Approaches

– Journal of Reproductive Immunology, 2026 (Review)

Contributors: Chiara Alfarè; Emma M. Giesen; Evelyn A. Huhn; Tullio Ghi; Stefan Verlohren; Sandra M. Blois

Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Published on by Cell Biologist

Dr. Ali Alahmari | Stem Cell Transplantation | Best Researcher Award

Kfshrc | Saudi Arabia

Dr. Ali Alahmari is a distinguished consultant in Acute Leukemia, Hematology, Hematopoietic Stem Cell Transplantation (HSCT), and Cellular Therapy at King Faisal Specialist Hospital & Research Centre. He earned his MBBS degree from King Saud University and completed his internship at King Khalid University Hospital. He has held a key consultant position, contributing extensively to the advancement of cellular therapy and bone marrow transplantation in Saudi Arabia. Dr. Alahmari has made significant academic contributions to the field, particularly in hemato-hepatology and sickle cell disease. His research has focused on novel transplant approaches, including haploidentical stem cell transplantation after liver transplantation and donor impact in severe aplastic anemia. He has co-authored over 22 scientific documents, with his work accumulating more than 629 citations and earning an h-index of 12, reflecting the depth and influence of his research. His notable publications include titles such as “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia“ and “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction.” Dr. Alahmari’s ongoing efforts continue to shape clinical best practices and research frameworks for hematologic disorders and transplantation medicine in the region.

Profile: Scopus

Featured Publications:

  • “Author Correction: Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic anemia: a study of the SAAWP EBMT”

  • “Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia”

  • “Haplo-stem cell transplant post liver transplantation to cure sickle cell disease with related liver dysfunction: a case series”

  • “Hematopoietic Stem Cell Transplantation in Sickle Cell Disease”

  • “Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation”

  • “Outcomes of human leukocyte antigen matched sibling transplant from consanguineous versus non-consanguineous parents, a single center experience”

Hannah Wen | Breast Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Hannah Wen | Breast Cancer | Best Researcher Award

Dr. Hannah Wen, MEMORIAL SLOAN KETTERING CANCER CENTER, United States

Dr. Hannah Y. Wen, M.D., Ph.D., is a distinguished breast cancer pathologist and cancer researcher at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. With dual training in medicine and cancer biology, Dr. Wen’s career reflects a deep commitment to advancing the field of translational oncology. Her research focuses on triple-negative breast cancer (TNBC), rare breast tumor subtypes, and predictive/prognostic biomarkers. Dr. Wen is a prolific academic contributor with publications in high-impact journals such as Nature Communications and Cancer Research. She integrates molecular biology with diagnostic pathology to improve cancer stratification and therapy decisions. In addition to her investigative work, she contributes as a principal investigator on multiple IRB-approved studies at MSKCC. Recognized with early academic accolades and continuously advancing the frontiers of cancer pathology, Dr. Wen exemplifies the blend of scientific rigor and clinical relevance. She is a strong candidate for any prestigious research award in pathology and oncology.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Academic Training
    Dr. Wen holds an M.D. from Peking University Health Science Center, one of China’s top medical schools, and a Ph.D. in Cancer Biology from MD Anderson Cancer Center, a global leader in cancer research.

  2. Robust Postdoctoral and Clinical Research Experience
    Her postdoctoral work at Genentech Inc. and ongoing clinical-scientific role at Memorial Sloan Kettering Cancer Center (MSKCC) place her at the intersection of innovative molecular research and high-impact clinical diagnostics.

  3. High-Impact Publications
    She has authored landmark papers in journals like Cancer Research, Nature Cell Biology, PNAS, Modern Pathology, and Nature Communications, covering diverse areas such as:

    • Triple-negative breast cancer

    • Genetic markers (e.g., BRCA1, p202)

    • Molecular subtyping of rare breast tumors

    • Pathologic stratification of early-stage breast cancer

  4. Active Investigator and IRB Leadership
    Dr. Wen is Principal Investigator for multiple MSK IRB protocols involving rare breast cancer subtypes and molecular markers. This shows strong leadership in translational research.

  5. Recognition and Consistency
    From receiving Top 10 Student Awards in Beijing to leading diagnostic-pathologic breakthroughs in 2025, her excellence spans over three decades.

Areas for Improvement:

  1. Visibility of Awards in the U.S. Academic System
    While her early academic awards are impressive, more documented recent honors, society memberships, or fellowships could further enhance her candidacy.

  2. Mentorship and Teaching Roles
    While likely involved, specific mention of mentorship, educational leadership, or curriculum development would strengthen her profile in academic impact.

  3. Interdisciplinary Collaborations
    Explicit examples of cross-disciplinary collaborations (e.g., computational oncology, AI in pathology) would underscore her innovation potential in modern biomedical research.

Education:

Dr. Hannah Y. Wen obtained her M.D. from Peking University Health Science Center, Beijing, China (1988–1993), where she was consistently recognized as an outstanding student. She pursued her Ph.D. in Cancer Biology at the University of Texas Health Science Center/MD Anderson Cancer Center in Houston, TX (1997–2001), focusing on molecular oncology. During her Ph.D., she contributed significantly to understanding interferon-inducible proteins in cancer suppression. Her educational journey reflects deep interdisciplinary training, combining clinical medicine with cutting-edge research. This robust academic background has laid the foundation for her success in translational cancer research and diagnostic pathology. Dr. Wen’s training continues with postdoctoral work at Genentech Inc. in Experimental Pathology, which further honed her molecular diagnostic skills. Her global academic trajectory—from China to elite U.S. institutions—has shaped her into a well-rounded researcher capable of addressing complex challenges in breast cancer diagnosis and treatment.

Experience:

Dr. Wen brings over two decades of research and clinical experience in cancer biology and diagnostic pathology. After completing her Ph.D. at MD Anderson Cancer Center, she conducted postdoctoral research in Experimental Pathology at Genentech, Inc., South San Francisco (2002–2003). Since then, she has held a faculty position at the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center. At MSKCC, Dr. Wen has served as Principal Investigator on multiple IRB-approved protocols investigating rare breast cancer subtypes and genetic alterations. Her daily work bridges histopathology and genomics to advance precision medicine in breast cancer. Beyond research, she mentors fellows and contributes to academic committees, reinforcing her role as a leader in her field. Her hands-on experience with triple-negative breast cancer, breast tumor markers, and breast pathology variants gives her a rare clinical-research dual expertise, making her a vital figure in contemporary breast cancer diagnostics.

Awards and Honors:

Dr. Hannah Y. Wen has received numerous recognitions throughout her academic journey. Early in her career, she was honored with the Outstanding Student Award by Peking University Health Science Center (1988–1992), a distinction granted to top-tier medical students. She was also named among Beijing’s Top 10 Outstanding Students in 1992, recognizing her academic and leadership excellence. While formal awards during her U.S. career are not extensively documented in the data provided, Dr. Wen’s growing impact in high-impact journals and role as a Principal Investigator at MSKCC are implicit accolades in the competitive world of academic medicine. Her contributions to translational breast cancer research, including studies on BRCA1 inactivation and tumor progression markers, underscore her continuous excellence. Given her record of impactful research and professional standing at one of the world’s leading cancer centers, she remains a strong contender for recognition such as the Best Researcher Award.

Research Focus:

Dr. Wen’s research centers on triple-negative breast cancer (TNBC), a challenging and aggressive subtype of breast cancer with limited therapeutic targets. She also investigates rare and under-recognized breast tumor subtypes such as microglandular adenosis, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. Her work involves the identification of predictive and prognostic markers, employing techniques such as targeted gene sequencing, BRCA1 methylation analysis, and molecular stratification models. As Principal Investigator, she leads studies under MSK IRB Protocols #16-411 and #16-596, exploring the genomic and epigenetic landscape of TNBC. Her research stands out for its clinical translation, directly impacting patient diagnosis and treatment planning. Recent contributions to Nature Communications and Modern Pathology show her innovative use of multimodal histopathological models and molecular profiling. Dr. Wen’s research reflects a powerful blend of diagnostic pathology, molecular genetics, and precision oncology—positioning her as a leader in breast cancer research.

Publications Top Notes:

  1.  The Role of Platelet Activating Factor in Reproduction – Progress of Anatomical Sciences (1996)

  2.  Transforming Growth Factor-α and Its Receptor in Reproduction – Medical Sciences (1997)

  3.  TGF-α Expression in Mouse Embryos and Uterus – J. Beijing Medical Univ. (1997)

  4.  p202 Slows Prostate Cancer Cell Growth – Oncogene (1999)

  5.  p202 Enhances TNF-α-Induced Apoptosis in Breast Cancer – Cancer Research (2000)

  6.  β-catenin as a Prognostic Marker in Breast Cancer – PNAS USA (2000)

  7.  HER-2/neu Drives Androgen-Independent Prostate Cancer – Cancer Research (2000)

  8.  EGFR’s Nuclear Role as a Transcription Factor – Nature Cell Biology (2001)

  9.  p202 Mediates Anti-Tumor Activity in Pancreatic Cancer – Cancer Research (2001)

  10.  Systemic Tumor Suppression via Bik Gene – Cancer Research (2002)

Conclusion:

Dr. Hannah Y. Wen is a highly qualified and deserving nominee for the Best Researcher Award. Her outstanding academic background, consistent and impactful research output, and leadership in breast cancer pathology make her a top-tier researcher in the field of translational oncology. She excels in integrating molecular biology with diagnostic pathology to improve cancer detection, stratification, and treatment.

With minor enhancements in visibility and cross-disciplinary leadership, Dr. Wen is not only suitable but a model candidate for this award. Her work is advancing breast cancer care at both the bench and bedside—fulfilling the core mission of research excellence.

Salvatore Chirumbolo | Cellular Stress Response | Innovative Research Award

Published on by Cell Biologist

Dr. Salvatore Chirumbolo | Cellular Stress Response | Innovative Research Award

Dr. Salvatore Chirumbolo, Università di Verona, Italy

Dr. Salvatore Chirumbolo is a distinguished Clinical Biochemist and Senior Researcher at the University of Verona, Department of Engineering for Innovation Medicine. He has made pioneering contributions in oxidative stress, immunopharmacology, systems biology, and ozone therapy. Author of over 400 scientific papers and several books, he is among Italy’s most cited biomedical scientists with an h-index of 46. His innovative work includes developing models for chaotic modulation in redox biology and proposing the concept of Shannon dissipation as a thermodynamic foundation for life. Dr. Chirumbolo has extensive editorial experience, serving on the boards of renowned journals including Scientific Reports, International Immunopharmacology, and Molecules. He actively collaborates with international institutions across Europe and promotes integrative, transdisciplinary biomedical approaches. His dedication to biophysical complexity and system-based innovation continues to influence translational medicine, making him an ideal nominee for the Research for Innovative Research Award.

Publication Profile:

Google Scholar

Scopus

✅ Strengths for the Award:

  1. Innovative Scientific Contributions:
    Dr. Chirumbolo’s concept of Shannon dissipation as the thermodynamic foundation of life represents a paradigm shift in theoretical biology. His model bridges information theory with biogenesis, advancing the frontiers of systems immunology and biological epistemology.

  2. Translational Research in Ozone Therapy:
    His chaotic modulation model for medical ozone effects introduces a systems-level interpretation of therapeutic mechanisms, with significant implications for redox biology, regenerative medicine, and inflammation management.

  3. Prolific Academic Output:
    With over 400 publications indexed in Scopus and Google Scholar, and an h-index of 46, Dr. Chirumbolo demonstrates sustained academic productivity, peer recognition, and impact in biomedical sciences.

  4. Editorial and Leadership Roles:
    He is actively involved with high-impact journals including Scientific Reports (Nature portfolio), International Immunopharmacology, and Molecules, contributing to global scientific discourse.

  5. Global Collaborations:
    His affiliations with institutions in Norway, Ukraine, Romania, Poland, and Italy reflect his commitment to cross-border scientific exchange and integrative research efforts.

🔧 Areas for Improvement:

  1. Patent and Industry Translation:
    Despite deep theoretical and experimental knowledge, Dr. Chirumbolo’s portfolio currently lacks patents or industrial consultancy projects. Advancing translational aspects of his models into commercial or clinical applications would enhance real-world impact.

  2. Public Communication and Outreach:
    While academically prolific, wider dissemination of his findings to non-specialist or policy-making audiences could increase societal relevance and interdisciplinary uptake.

🎓 Education:

Dr. Chirumbolo earned his Medical Specialization in Biochemical Chemistry in 1995, marking the beginning of his journey in biomedical sciences. His academic roots are grounded in clinical biochemistry, molecular biology, and translational medicine. He trained in Italy’s National Health System, where he directed various molecular biology laboratories, gaining firsthand experience in diagnostic innovation and experimental biochemistry. With a strong foundation in cellular and molecular biology, his educational path laid the groundwork for his systems-level understanding of biological complexity. His commitment to continuous learning is evident in his interdisciplinary research spanning immunology, redox biology, information theory, and ozone therapy. He is actively engaged in scientific discourse through editorial appointments and international conferences, nurturing the next generation of systems biologists and medical scientists. His academic lineage blends traditional biochemical education with pioneering insights into biological epistemology and complex systems science.

🧪 Experience:

Dr. Chirumbolo has over three decades of professional experience in biochemistry, molecular biology, and translational research. Starting in Italy’s National Health System, he directed molecular labs focusing on clinical diagnostics and immunological assays. He later transitioned to academia, becoming a Senior Researcher at the University of Verona. He has led major research initiatives involving oxidative stress, basophil biology, and the use of phytochemicals in chronic diseases. As an editor for journals like Scientific Reports, International Immunopharmacology, and Molecules, he has shaped international scientific dialogue. His collaborations span Italy, Norway, Ukraine, Romania, and Poland, involving diverse domains such as chemical biology and clinical immunology. He also contributes to bioinformatic modeling of redox systems and life origin theories. With over 400 indexed publications, Dr. Chirumbolo’s multidisciplinary expertise bridges clinical and theoretical biosciences, driving innovative solutions in modern medicine.

🔬 Research Focus:

Dr. Chirumbolo’s research focuses on biomedical systems, oxidative stress, and the thermodynamic foundations of life. He developed the novel concept of Shannon dissipation, linking informational entropy to the emergence of biological life, aligning with thinkers like Varela and Maturana. His work in ozone therapy led to the formulation of chaotic modulation models that explain its redox-based medical efficacy. He also investigates bioinformatic modeling, basophil signaling, phytochemical impacts, and nutraceutical interventions in chronic inflammation, allergy, and metabolic disorders. His models propose mechanistic insights into cell signaling and antioxidant networks, enhancing therapeutic targeting. Recent contributions include exploring the microvascular effects of SARS-CoV-2, the interface of redox dynamics and cellular adaptation, and ozone’s systemic regulatory properties. Through extensive collaborations, he integrates cellular, chemical, and systems-level research to push the boundaries of personalized and integrative medicine.

📚 Publications Top Notes:

  • 🧪 Ozone therapy addresses neuropathic pain in ulcerous wounds

  • 🍊 Something more about the role of flavonoids in aging

  • 🩸 Prolonged alterations in red blood cell rheology following mild SARS-CoV-2 infection: Implications for microvascular health

  • 💉 Intravenous glutathione should not be mismatched with ozone as an antioxidant therapy

  • 🌬️ Sonic transdermal transfer of ozone and its use in oxygen-ozone therapy. Wheat and chaff

  • 🧬 Effect of SARS-CoV2 S protein on red blood cells parameters. Some comments

  • ⚠️ Adverse effects following some practices of ozone therapy for disc herniation. Critical comments

  • 🧠 Post-infective myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID as two puzzling faces of the same medal

  • 🦴 Synovial Fluid as a Crucial Component of the Joint Microenvironment in Rheumatoid Arthritis

  • ❤️ Aetiology and clinical manifestations of patients with non-dilated left ventricular cardiomyopathy. Some comments

🧾 Conclusion:

Dr. Salvatore Chirumbolo is highly suited for the Research for Innovative Research Award. His work exemplifies pioneering thought, multidisciplinary integration, and scientific originality. From foundational biological theory to clinically relevant applications like ozone therapy and oxidative stress modulation, his contributions address both the “why” and “how” of living systems. His influence is evident in his citation record, editorial appointments, and leadership in cutting-edge biomedical modeling.